{"id":23309,"date":"2026-09-27T07:14:03","date_gmt":"2026-09-27T07:14:03","guid":{"rendered":"https:\/\/drtaherabuhejleh.com\/?p=23309"},"modified":"2026-09-29T08:36:31","modified_gmt":"2026-09-29T08:36:31","slug":"important-updates-from-wclc-2026","status":"publish","type":"post","link":"https:\/\/drtaherabuhejleh.com\/ar\/important-updates-from-wclc-2026\/","title":{"rendered":"Important Updates from WCLC 2026"},"content":{"rendered":"<ol class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/phase-3-destiny-lung04-trial-shows-first-line-trastuzumab-deruxtecan\">DESTINY-Lung04 \u2014 1L trastuzumab deruxtecan in HER2-mutant NSCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/late-breaking-harmoni-2-analysis-shows-ivonescimab-significantly-improves\">HARMONi-2 \u2014 ivonescimab vs pembrolizumab in 1L PD-L1-positive advanced NSCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/zipalertinib-plus-chemotherapy-significantly-extends-progression-free\">REZILIENT 3 \u2014 zipalertinib + chemotherapy in EGFR exon 20 insertion NSCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/papillon-study-first-line-amivantamab-chemotherapy-demonstrates-longest\">PAPILLON \u2014 final OS with amivantamab + chemotherapy in EGFR exon 20 insertion NSCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/eight-year-adaura-update-shows-sustained-overall-survival-benefit-adjuvant\">ADAURA \u2014 8-year update of adjuvant osimertinib<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/zidesamtinib-demonstrates-94-response-rate-tki-naive-patients-advanced\">ARROS-1 \u2014 zidesamtinib in ROS1-positive NSCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/phase-iii-maverick-trial-supports-brain-mri-surveillance-alone-standard\">MAVERICK \/ SWOG S1827 \u2014 MRI surveillance vs PCI in SCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/phase-iii-artemis-008-trial-shows-risvutatug-rezetecan-significantly\">ARTEMIS-008 \u2014 risvutatug rezetecan vs topotecan in relapsed SCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/phase-iii-taishan-302-trial-shows-tam-peli-significantly-improves-survival\">TAISHAN-302 \u2014 tambotatug pelitecan vs topotecan in relapsed SCLC<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/subcutaneous-tarlatamab-shows-favorable-safety-profile-and-antitumor\">Tarlatamab program \u2014 DeLLphi-309 \/ DeLLphi-308<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.iaslc.org\/iaslc-news\/press-release\/sacituzumab-govitecan-plus-pembrolizumab-does-not-meet-primary-endpoints\">EVOKE-03 \/ KEYNOTE-D46 \u2014 sacituzumab govitecan + pembrolizumab in PD-L1 \u226550% NSCLC<\/a><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Taher Abu Hejleh<\/p>","protected":false},"excerpt":{"rendered":"<p>Taher Abu Hejleh<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[183],"tags":[],"class_list":["post-23309","post","type-post","status-publish","format-standard","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/posts\/23309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/comments?post=23309"}],"version-history":[{"count":1,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/posts\/23309\/revisions"}],"predecessor-version":[{"id":23311,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/posts\/23309\/revisions\/23311"}],"wp:attachment":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/media?parent=23309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/categories?post=23309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/tags?post=23309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}